Risk of endometrial cancer following cessation of menopausal hormone use (Washington, United States)
While there are a number of benefits to the health of postmenopausal women from use of unopposed estrogens, the increased risk of endometrial cancer related to these hormones has led many women to use combined estrogen-progestogen therapy instead, or not to use hormones at all. Most women who take hormones do so only in the early portion of their postmenopausal years, so the risk of endometrial cancer following cessation of use might bear heavily on the overall risk/benefit evaluation. We analyzed data from a case-control study of women in western Washington (United States) to assess the magnitude of excess risk of endometrial cancer following discontinuation of estrogen use. Cases (n = 661) consisted of women aged 45 to 74 diagnosed between 1985 and 1991 who resided in one of three countries in Washington State. Controls (n = 865) were identified by random-digit dialing. Subjects were interviewed in-person to ascertain current and prior hormone use. The analysis was restricted to women who had not received combined estrogen-progestin therapy. Among women who had used unopposed estrogens at some time, risk of endometrial cancer declined as time since last use increased. Nonetheless, even among women who used these hormones for just a few years, the risk remained elevated by 30 to 70 percent almost a decade after cessation. These results, combined with those of most (but not all) other studies of this issue, suggest that a women who has discontinued unopposed estrogen therapy may retain a small increased risk of endometrial cancer for a long period of time.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1996 |
|---|---|
| Erschienen: |
1996 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Cancer causes & control : CCC - 7(1996), 6 vom: 12. Nov., Seite 575-80 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Green, P K [VerfasserIn] |
|---|
| Themen: |
Estrogens |
|---|
| Anmerkungen: |
Date Completed 08.04.1997 Date Revised 24.10.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM088999033 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM088999033 | ||
| 003 | DE-627 | ||
| 005 | 20231222075115.0 | ||
| 007 | tu | ||
| 008 | 231222s1996 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0297.xml |
| 035 | |a (DE-627)NLM088999033 | ||
| 035 | |a (NLM)8932917 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Green, P K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk of endometrial cancer following cessation of menopausal hormone use (Washington, United States) |
| 264 | 1 | |c 1996 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.1997 | ||
| 500 | |a Date Revised 24.10.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a While there are a number of benefits to the health of postmenopausal women from use of unopposed estrogens, the increased risk of endometrial cancer related to these hormones has led many women to use combined estrogen-progestogen therapy instead, or not to use hormones at all. Most women who take hormones do so only in the early portion of their postmenopausal years, so the risk of endometrial cancer following cessation of use might bear heavily on the overall risk/benefit evaluation. We analyzed data from a case-control study of women in western Washington (United States) to assess the magnitude of excess risk of endometrial cancer following discontinuation of estrogen use. Cases (n = 661) consisted of women aged 45 to 74 diagnosed between 1985 and 1991 who resided in one of three countries in Washington State. Controls (n = 865) were identified by random-digit dialing. Subjects were interviewed in-person to ascertain current and prior hormone use. The analysis was restricted to women who had not received combined estrogen-progestin therapy. Among women who had used unopposed estrogens at some time, risk of endometrial cancer declined as time since last use increased. Nonetheless, even among women who used these hormones for just a few years, the risk remained elevated by 30 to 70 percent almost a decade after cessation. These results, combined with those of most (but not all) other studies of this issue, suggest that a women who has discontinued unopposed estrogen therapy may retain a small increased risk of endometrial cancer for a long period of time | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, U.S. Gov't, P.H.S. | |
| 650 | 7 | |a Estrogens |2 NLM | |
| 650 | 7 | |a Progestins |2 NLM | |
| 700 | 1 | |a Weiss, N S |e verfasserin |4 aut | |
| 700 | 1 | |a McKnight, B |e verfasserin |4 aut | |
| 700 | 1 | |a Voigt, L F |e verfasserin |4 aut | |
| 700 | 1 | |a Beresford, S A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer causes & control : CCC |d 1993 |g 7(1996), 6 vom: 12. Nov., Seite 575-80 |w (DE-627)NLM012922145 |x 1573-7225 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:1996 |g number:6 |g day:12 |g month:11 |g pages:575-80 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 1996 |e 6 |b 12 |c 11 |h 575-80 | ||